Neurotrope, Inc., 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036.
Neurotrope, Inc., 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036.
Trends Pharmacol Sci. 2019 Sep;40(9):655-668. doi: 10.1016/j.tips.2019.07.008. Epub 2019 Aug 8.
Alzheimer's disease (AD), the leading disorder of memory impairment in our aging population, is increasing at an alarming rate. AD is currently identified by three 'gold standard criteria': (i) dementia in life, (ii) amyloid plaques at autopsy, and (iii) neurofibrillary tangles at autopsy. Several autopsy studies have indicated that dementia in life is a consequence of lost synaptic networks in the brain, while many clinical trials targeting neurotoxic amyloid beta (Aβ) have consistently failed to produce therapeutic effects on memory function in AD patients. Restoring cognitive function(s) by activating endogenous repairing/regenerating mechanisms that are synaptogenic and antiapoptotic (preventing neuronal death), however, is emerging as a necessary disease-modifying therapeutic strategy against AD and possibly for other degenerative dementias, such as Parkinson's disease and multi-infarct dementia.
阿尔茨海默病(AD)是导致我们老龄化人口记忆障碍的主要疾病,其发病率正在以惊人的速度增长。AD 目前通过三个“金标准”来确定:(i)生活中的痴呆症,(ii)尸检中的淀粉样斑块,以及(iii)尸检中的神经原纤维缠结。几项尸检研究表明,生活中的痴呆症是大脑中失去突触网络的结果,而许多针对神经毒性淀粉样β(Aβ)的临床试验一直未能对 AD 患者的记忆功能产生治疗效果。然而,通过激活具有突触发生和抗细胞凋亡作用的内源性修复/再生机制(防止神经元死亡)来恢复认知功能,正成为对抗 AD 以及可能对抗帕金森病和多发性梗塞性痴呆等其他退行性痴呆的必要疾病修饰治疗策略。